Boston Scientific Corp
BSX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$98.00 | Kzzcktk | Yjghpccd |
Boston Scientific Is Well-Positioned To Expand Its Presence in Electrophysiology
Business Strategy and Outlook
Boston Scientific has solidified its footing as one of three major cardiac device makers and significantly improved its innovation and operational chops. Boston remains a tough competitor—even a prolonged period of operational and management upheaval from 2006 to 2014 wasn't enough to permanently impair the underlying business and Boston's ability to develop and commercialize new technology platforms. Under CEO Michael Mahoney, the firm has focused on introducing meaningful innovation and leveraging its historically formidable sales and marketing resources.